Medica Scientia Innovation Research
Budget
€10 — €0
EP Access
0
accredited persons
Staff
3
0.3 FTE
EU Grants
€161,630
Mission & Goals
We are an international research organization in clinical oncology. Our goal is to generate the most innovative clinical trials with the most promising drugs by fostering global collaborations between expert clinical investigators/kols and pharmaceutical companies/biotechs. I3LUNG is a European project funded under the framework of the Horizon Europe (HEurope) call “Ensuring access to innovative, sustainable and high-quality health care”. Our consortium gathers 16 partners with different expertise located worldwide, with the common goal of providing better assistance and individualize treatment for patients affected by metastatic lung cancer.
EU Legislative Interests
-Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use. -General Data Protection Regulation. -Artificial Intelligence Act. - European Health Data Space
Communication Activities
-AI for Oncology' Congress: annual congress organized by the Istituto Nazionale Dei Tumori (participating entity of the I3LUNG consortium). -AI & Health event developed by the I3LUNG project, funded by Horizon Europe. -Application for participation in the Computers Privacy and Data Protection Conference (CPDP).
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
https://www.medsir.org/i3lung-study
Organisation Members
Medica Scientia Innovation Research Corporation Registered in One Broadway, 14th Floor, Cambridge, Massachusetts, 02142, United States.
Commissioner Meetings
No recorded meetings with EU commissioners.